---
figid: PMC7961649__cancers-13-01132-g008
figlink: pmc/articles/PMC7961649/figure/cancers-13-01132-f008/
number: Figure 8
caption: FASN enables HER2-driven breast cancer resistance to tamoxifen. The stimulatory
  effects of estradiol on FASN expression can be blunted by anti-estrogens in endocrine-responsive
  ER-positive/HER2- negative breast cancer cells (left). In ER positive/HER2- positive
  breast cancer cells, however, an AKT/MAPK-related constitutive hyperactivation of
  FASN expression becomes unaltered in response to estradiol and could be further
  enhanced by tamoxifen (right). FASN pro-survival signaling is co-opted by HER2 pathway
  activation to enable breast cancer resistance to tamoxifen. FASN inhibitors may
  be clinically relevant to countering resistance to tamoxifen in luminal B-like,
  ER+/HER2+ breast carcinomas. Created with BioRender.com and Mindthegraph.com.
pmcid: PMC7961649
papertitle: Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer.
reftext: Javier A. Menendez, et al. Cancers (Basel). 2021 Mar;13(5):1132.
pmc_ranked_result_index: '1581'
pathway_score: 0.9461873
filename: cancers-13-01132-g008.jpg
figtitle: FASN enables HER2-driven breast cancer resistance to tamoxifen
year: '2021'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7961649__cancers-13-01132-g008.html
  '@type': Dataset
  description: FASN enables HER2-driven breast cancer resistance to tamoxifen. The
    stimulatory effects of estradiol on FASN expression can be blunted by anti-estrogens
    in endocrine-responsive ER-positive/HER2- negative breast cancer cells (left).
    In ER positive/HER2- positive breast cancer cells, however, an AKT/MAPK-related
    constitutive hyperactivation of FASN expression becomes unaltered in response
    to estradiol and could be further enhanced by tamoxifen (right). FASN pro-survival
    signaling is co-opted by HER2 pathway activation to enable breast cancer resistance
    to tamoxifen. FASN inhibitors may be clinically relevant to countering resistance
    to tamoxifen in luminal B-like, ER+/HER2+ breast carcinomas. Created with BioRender.com
    and Mindthegraph.com.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ERBB2
  - HRAS
  - KRAS
  - NRAS
  - ARAF
  - BRAF
  - RAF1
  - AKT2
  - AKT3
  - AKT1
  - MAP2K1
  - MAP2K2
  - ACACB
  - ACACA
  - FASN
  - MAPK3
  - MAPK1
  - TAM
  - TCA
  - Breast Cancer
genes:
- word: HER2/ERa
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: HER2/ERacross-talk
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: Acc
  symbol: ACC
  source: bioentities_symbol
  hgnc_symbol: ACACB
  entrez: '32'
- word: Acc
  symbol: ACC
  source: bioentities_symbol
  hgnc_symbol: ACACA
  entrez: '31'
- word: FASN
  symbol: FASN
  source: hgnc_symbol
  hgnc_symbol: FASN
  entrez: '2194'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: FASN
  symbol: FASN
  source: hgnc_symbol
  hgnc_symbol: FASN
  entrez: '2194'
- word: FASN
  symbol: FASN
  source: hgnc_symbol
  hgnc_symbol: FASN
  entrez: '2194'
- word: HER2-
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: HER2+
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
chemicals:
- word: TAM
  source: MESH
  identifier: C419191
- word: TCA
  source: MESH
  identifier: C000589078
diseases:
- word: Breast Cancer
  source: MESH
  identifier: D001943
---
